M.D. Anderson Cancer Center: Lymphoma, B-Cell trials

The registry lists 29 Lymphoma, B-Cell studies with M.D. Anderson Cancer Center as lead sponsor. 6 are open to participants now and 12 have results posted.

Early Phase 1 1Phase 1 10Phase 2 23No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT07283679Phase 1/2
• A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaRecruitingNCT06213311Phase 2
• A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell LymphomasRecruitingNCT05773040Phase 1
• A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingNCT05615636Phase 2
• Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
• Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell TherapyRecruitingNCT04870853
• Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell LymphomaCompletedNCT04432506Phase 2Results posted
• Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin LymphomasCompletedNCT04074746Phase 1/2Results posted
• Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT03019640Phase 2Results posted
• Smart Start: A Phase II Study of Rituximab, Lenalidomide, and IbrutinibCompletedNCT02636322Phase 2Results posted
• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC SubtypeTerminatedNCT02589145Phase 1/2Results posted
• A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell LymphomaCompletedNCT02529852Phase 1/2Results posted
• Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell LymphomaTerminatedNCT02272686Phase 2Results posted
• Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02199184Phase 2Results posted
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
• Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT01701986Phase 1/2Results posted
• Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or YoungerCompletedNCT00290498Phase 2Results posted
• Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00081861Phase 2Results posted
• A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell LymphomaWithdrawnNCT06670105Phase 2
• An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell LymphomaWithdrawnNCT05929716Phase 2
• Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin LymphomaWithdrawnNCT04220008Phase 2
• Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaCompletedNCT03770416Phase 2
• CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell LymphomaWithdrawnNCT03579927Phase 1/2
• CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
• A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell LymphomaWithdrawnNCT02532192Phase 1
• Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02405078Early Phase 1
• Rituximab + GM-CSF in Patients With Follicular B-Cell LymphomaCompletedNCT01939730Phase 2
• Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid MalignanciesTerminatedNCT00038883Not applicable
• Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With ChemotherapyCompletedNCT00038571Phase 2